| Literature DB >> 33980673 |
Biao Tang1, Yao Wang2, Yi Luo1, Xue Zheng1, Xiaoxia Qin2, Hua Yang3, Zhangqi Shen4.
Abstract
Previous studies indicated that Campylobacter has developed several mechanisms that confer resistance to florfenicol, which is used in food animal production. This study describes the coexistence of optrA and fexA in Campylobacter jejuni and Campylobacter coli isolates from pigs and poultry. Moreover, whole-genome sequencing data showed that the two genes are located in various multidrug resistance genomic islands within different regions of the Campylobacter genomes. The emergence of optrA and fexA may support the spread of florfenicol-resistant Campylobacter strains of animal origin.IMPORTANCE Florfenicol is widely used for the treatment of respiratory infections and as a feed additive in food animal production. As a foodborne pathogen, Campylobacter is constantly exposed to florfenicol, and resistance to this antimicrobial agent has increased in recent years. Previous studies indicated that Campylobacter has developed several mechanisms that confer resistance to florfenicol. This study describes for the first time the coexistence of the florfenicol exporter FexA and the ribosomal protective protein OptrA in Campylobacter jejuni isolated from pigs. The two genes were located in various multidrug resistance genomic islands within different regions of the Campylobacter genomes. Although phenicols are not commonly used for the treatment of Campylobacter infections, the extensive use of florfenicol in food animals may play a role in the coselection of multidrug resistance genomic island (MDRGI)-carrying Campylobacter isolates which also exhibited resistance to critically important antimicrobial agents (macrolides, aminoglycosides, and tetracyclines) commonly used for the treatment of human campylobacteriosis.Entities:
Keywords: Campylobacter; fexA; multidrug resistance; optrA
Year: 2021 PMID: 33980673 PMCID: PMC8125047 DOI: 10.1128/mSphere.00125-21
Source DB: PubMed Journal: mSphere ISSN: 2379-5042 Impact factor: 4.389
Isolation and genomic information of optrA+ fexA+ strains
| Isolate | Host | Species | Genome length (bp) | GC content (%) | MLST | Quality | MDRGI length (bp) | MDRGI GC content (%) | Accession no. |
|---|---|---|---|---|---|---|---|---|---|
| CC19DZ036 | Duck | Chromosome: 1,761,335 | 31.37 | ST828 | Completed | 11,195 | 36.22 | ||
| CC19DZ037 | Duck | Chromosome: 1,761,334 | 31.37 | ST828 | Completed | 11,195 | 36.22 | ||
| CC19PF050 | Pig | 1,798,069 | 30.21 | Unknown | Draft | ||||
| CC19PF065 | Pig | Chromosome: 1,681,082 | 30.57 | Unknown | Completed | 18,223 | 34.79 | ||
| pPF065-186: 186,647 | 26.41 | ||||||||
| pPF065-3: 3,395 | 31.37 | ||||||||
| CC19CH074 | Chicken | 1,831,137 | 31.16 | ST825 | Draft | ||||
| CC19CH075 | Chicken | Chromosome: 1,781,472 | 31.47 | ST825 | Completed | 18,553 | 36.36 | ||
| pCH075-80: 80,135 | 26.07 | ||||||||
| pCH075-4: 4,944 | 29.57 | ||||||||
| pCH075-3: 3,405 | 31.01 | ||||||||
| pCH075-2: 2,426 | 25.89 | ||||||||
| CC19CH076 | Chicken | Chromosome: 1,781,471 | 31.47 | ST825 | Completed | 18,553 | 36.36 | ||
| pCH076-80: 80,131 | 26.09 | ||||||||
| pCH076-4: 4,944 | 29.57 | ||||||||
| pCH076-3: 3,405 | 31.01 | ||||||||
| pCH076-2: 2,426 | 25.89 | ||||||||
| ZS007 | Duck meat | Chromosome: 1,658,567 | 30.55 | ST10317 | Completed | 22,697 | 38.01 | ||
| 1712SZ1KX20C | Chicken | 1,713,884 | 31.36 | ST825 | Draft | 9,611 | 36.79 |
MLST, multilocus sequence type.
Acquired drug resistance genes and MIC of optrA+ fexA+ isolates
| Isolate | Acquired drug resistance genes | MIC (μg/ml) of | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CIP | NAL | GEN | TET | CLI | ERY | AZM | TEL | FFC | ||
| CC19DZ036 | 16 | 64 | 0.5 | 32 | 4 | >64 | >32 | 32 | >32 | |
| CC19DZ037 | 16 | 128 | 0.5 | 32 | 4 | >64 | >32 | 32 | >32 | |
| CC19PF050 | 16 | >128 | >64 | >64 | >32 | >64 | >32 | 32 | >32 | |
| CC19PF065 | 16 | 128 | >64 | >64 | 16 | >64 | >32 | 32 | >32 | |
| CC19CH074 | 32 | 64 | >64 | 64 | >32 | 64 | 32 | 32 | >32 | |
| CC19CH075 | 32 | 64 | >64 | 64 | >32 | 64 | 16 | 16 | >32 | |
| CC19CH076 | 32 | 64 | 64 | 64 | >32 | >64 | 32 | 16 | >32 | |
Abbreviations: CIP, ciprofloxacin; NAL, nalidixic acid; GEN, gentamicin; TET, tetracycline; CLI, clindamycin; ERY, erythromycin; AZM, azithromycin; TEL, telithromycin; FFC, florfenicol. CLSI- or NARMS-approved breakpoint concentrations for resistance, in micrograms per milliliter, are as follows: CIP, 4; NAL, 32; GEN, 4; TET, 16; CLI, 8; ERY, 32; AZM, 1; TEL, 8; FFC, 8.
FIG 1Genetic environment of optrA in the genomes of C. jejuni isolates and comparison of the optrA-carrying regions. Arrows indicate the transcription direction. Regions of >90% homology are marked with gray shading. Genes are differentiated by different colors.